CERE Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinsonís disease and substance use disorder.

$15.46  -0.41 (-2.58%)
As of 03/02/2021 15:58:24 EST     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Mid cap
Health Care
Biotechnology
USA
USA
07/30/2020
127,123,954
266,664
$2,017,457,150
0.00%
SEC Edgar Online
10-Q
10-K
15678U128
US15678U1280
BMVMJ12

Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
0.00
0.00
0.00
0.00%
0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy